Prelude Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Hold |
0
| – | – | – | 1677 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 1847 |
|
|
2019
Q2 | – | Sell |
-136
| Closed | -$7K | – | 1796 |
|
|
2019
Q1 | $7K | Sell |
136
-153
| -53% | -$7.88K | ﹤0.01% | 1214 |
|
|
2018
Q4 | $12K | Buy |
289
+153
| +113% | +$6.35K | ﹤0.01% | 1006 |
|
|
2018
Q3 | $9K | Sell |
136
-3,271
| -96% | -$216K | ﹤0.01% | 1131 |
|
|
2018
Q2 | $258K | Buy |
+3,407
| New | +$258K | 0.02% | 550 |
|
|
2018
Q1 | – | Sell |
-3,407
| Closed | -$182K | – | 1605 |
|
|
2017
Q4 | $182K | Sell |
3,407
-611
| -15% | -$32.6K | 0.01% | 562 |
|
|
2017
Q3 | $240K | Buy |
4,018
+1,400
| +53% | +$83.6K | 0.02% | 526 |
|
|
2017
Q2 | $207K | Buy |
+2,618
| New | +$207K | 0.02% | 506 |
|
|
2017
Q1 | – | Sell |
-3,260
| Closed | -$259K | – | 1782 |
|
|
2016
Q4 | $259K | Buy |
3,260
+2,830
| +658% | +$225K | 0.03% | 450 |
|
|
2016
Q3 | $30K | Buy |
+430
| New | +$30K | ﹤0.01% | 1157 |
|
|
2014
Q4 | – | Sell |
-100
| Closed | -$1K | – | 2077 |
|
|
2014
Q3 | $1K | Buy |
+100
| New | +$1K | ﹤0.01% | 1707 |
|